To develop therapeutic approaches to restore and activate STING signaling and enhance immunogenicity in KRAS and LKB1 co-mutant lung cancer, Kitajima et al. (2022) performed a drug screen and identified inhibition of MPS1 to activate cGAS-STING pathway signaling. Here, KRAS is linked to lung carcinoma.